Ngaahi tu'unga 'o e fili 'o e kau tu'uaki peptide 2026: 'Oku 'Ikai Toe Fakapapau'i 'e he Scale .

Tali vave

Scale is table stakes in peptide supplier selection. Score suppliers on responsiveness, ngaahi fakalelei, analytical transparency and technical collaboration.

Ko e Vakai Angamaheni .: Ko e Scale Ko e Fili Malu .

Mo e konga lahi ‘o e hongofulu‘i ta‘u kuohilí ., ko e tali tefito ki he ngaahi tu'unga fili 'o e kau tu'uaki peptide kuo faingofua .: tu'unga 'uluaki 'a e malava. Tier-1 CDMOs mo e ngaahi tohi va'inga fakatau 'oku langa takatakai 'iate kinautolu 'oku nau tokanga'i 'a e me'afua 'o e ngaohi ., reactor voliume mo e saiti lau ko e ngaahi faka'ilonga tefito de-fakatu'utamaki ., ‘i he fakakaukau ko ha kautaha ngaohi lahi pē ‘e lava ke ne fakapapau‘i ‘a e tu‘uaki ‘i he taimi ‘oku tupulaki ai ‘a e fiema‘ú ..

Na‘e ma‘u ‘e he vakai ko iá hono tu‘ungá .. Ko e si'isi'i 'o e malava 'o fakafou 'i he kuonga GLP-1 na'e mo'oni ., pea ko e kau supplier na'a nau fakahoko 'a e kolomu'a vave na'a nau solova mo'oni ha palopalema 'o e supply .. Ko e fakalahi ‘o e peptide ‘oku fakafuofua ki he €900 miliona ‘a e CordenPharma, na‘e fanongonongo ai ‘i Siulai 2012 . 2024, tānaki atu ‘a e ngaahi lēlue ngaohi‘anga koloa lalahi ‘i Kololato pea tānaki atu ki ai ha feitu‘u ‘Iulope ‘oku ‘i ai ‘a e greenfield .. Fale ‘o Bachem K ., ko hono fu‘u ‘akau lahi ‘i Bubendorf ., taula CHF 332.6 miliona 'o e 'inivesimeni FY2025 pea fakakakato 'a e liliu kuo fakaha mei he CDMO ki he CMO ki he industrial-scale ., output voliume-ma'olunga.

Ngaahi tu'unga 'o e fili 'o e kau tu'uaki peptide 2026: 'Oku 'Ikai Toe Fakapapau'i 'e he Scale .

Naʻe ʻikai ʻaupito ko e tali hala ʻa e meʻafuá .. ‘Oku ‘ikai pē ke kei hoko ia ko e taha pē ..

Ko e hā naʻe taʻofi ai ʻe he Scale ʻa e hoko ko e Fakafaikehekeheʻí .

ko ha panel tafa'aki-ki-he-taha 'oku fakahaa'i ai ha laine onboarding CDMO tier-1 fakafepaki'i ha founga-fe'ave'aki 'o e matapa sio'ata 'o e kautaha fakatau, mo e . 2-4 uike versus mahina lahi c .

Kuo tuku 'e he capacity 'a e fakamavahe'i 'o e kau supplier he 'oku fakatau 'e he taha kotoa 'a e capacity tatau 'i he taimi tatau .. 'I he taimi 'oku fekau'i ai 'e ha ngaahi CDMOs 'a e ngaahi fu'u 'akau peptide lalahi 'i he matapa sio'ata tatau ., ko e fakangatangata na'e ngaue'aki ke fakahokohoko 'a e mala'e 'oku hoko ia ko ha tu'unga fakamole vahevahe kae 'ikai ko ha lelei vahevahe .. Ko e ngaahi palopalema ‘e tolu ‘oku muimui mai mei hono faito‘o ‘a e me‘afuá ko e fili malu ia ..

Ngaahi tu'unga 'o e fili 'o e kau tu'uaki peptide 2026: 'Oku 'Ikai Toe Fakapapau'i 'e he Scale .

Ko e 'uluaki ko e langa 'a e malava 'oku fakapa'anga-fakamole mo e dilutive kimu'a pea toki accretive .. Na’e holo ‘a e EBIT ‘a e Bachem ki he 100. 22.0% in FY2024 from 22.4%, which the company attributed to “increased depreciation and amortization on new investments” in its FY2024 results release. The pattern repeated in the first half of 2026, when the company stated that “ramp-up costs for Building K affected the operating result as expected” in the most recent interim report. New capacity costs margin before it earns any.

The second problem is that where growth did arrive, it came from utilization and mix rather than from scale itself. Bachem’s Commercial API growth in the first half of 2025 was “mainly driven by a good operational execution across our network that led to an optimized utilization of existing facilities,” according to Bachem’s H1 2025 ngaahi ola. Filling existing plants better, not owning more of them, hiki e fika ..

Ko e palopalema hono tolu ko e manifinifi ange 'a e fakakikihi 'o e laulahi 'i he tupulaki 'o e 'ulu'i fakamatala 'oku fokotu'u mai .. Na’e holo ‘a e pa’anga hū mai ‘a e GenScript ‘i he FY2025 61.4%, ka Ko e ola ‘o e GenScript ‘i he FY2025 faka'ilonga'i 'a e me'a ko ia 'oku tefito ki he pa'anga hū mai mei he laiseni, tautautefito ki he laiseni si'isi'i 'o e LaNova, lolotonga ia ko e ProBio’s . 309.1% 'oku mio'i 'a e tupu 'e he ngaahi me'a taimi 'e taha pea tupulaki 'a e totongi-ki-he-sevesi . 21%. Ko e ngaahi peseti 'ulu'i fakamatala heni 'oku ne fua 'a e taimi 'o e aleapau ., 'ikai ko e malava 'o e ngaue.

Ka fakatau 'e he kau va'inga mamafa kotoa pe 'a e malava tatau ., peptide supplier fili 'a e ngaahi tu'unga 'o e hiki ki he me'a 'oku 'ikai lava ke fakatau 'e he malava: tali tali, ngaahi fakalelei makehe, 'analaiso 'a e mahino, mo e fengaue'aki fakatekinikale ..

Ko e hā ʻoku fakahaaʻi moʻoni ʻe he fakamatala fekauʻaki mo e ngaahi tuʻunga fili ʻo e kau tuʻuaki ʻo e Peptide .

Toe lau 'a e ngaahi fika kuo fakahaa'i pea 'oku inverts 'a e fakatata .. Ko e GenScript H1. 2026 ngaahi ola fakataimi 'o 'ai 'a e pa'anga hu mai fakakatoa ki he fakafuofua ki he US$404.2 miliona ., olunga 27.3% ta‘u ki he ta‘u ‘i ha tu‘unga fakafehoanaki .; ko e lipooti ola ‘o e FY2025 ‘oku $959.5 miliona mo e . 66,000+ kau kasitoma 'o e Kulupu Saienisi 'o e Mo'ui. Ko e ngaahi fika ia 'o e laulahi 'o e laine-sevesi .. 'Oku 'ikai ha taha 'o e ngaahi peesi ola 'o e GenScript 'oku lau ki he fakafehoanaki ko 'eni 'oku ne fakahaa'i ha laine pa'anga hū mai peptide-pau ., fika 'o e malava pe faka'ilonga 'o e liliu, pea ko e tafa'aki ko ia 'o e fakafehoanaki 'oku makatu'unga ia 'i he fakahaa'i fakapule'anga manifinifi ange 'i he tafa'aki 'o e Bachem .. Ko e 'ikai ke 'i ai ko e ma'u ..

Bachem’s H1 2025 'Oku fakahaa'i 'e he ola 'a e fakatau 'o e CHF . 313.0 miliona, olunga 30.2%, pea mo ha EBITDA 'o e 100.000. 29.1%, hake mei he 23.1% ʻi ha taʻu ʻe taha kimuʻa. Ko e tupulaki 'o e fotunga ko ia na'e ha'u ia mei hono faka'aonga'i lelei ange 'o e ngaahi me'angaue 'oku 'osi lele 'a e Bachem ., 'ikai mei he malava fo'ou ..

Ko e ngaahi tu'unga 'e fa 'oku nau 'ave 'a e mamafa kae 'ikai .: tali tali, ngaahi fakalelei'i makehe 'o e peptide, peptide 'analaiso 'a e fakamatala 'o e mahino, mo e peptide CDMO fakatekinikale 'a e fengaue'aki .. Ko e fakamo'oni 'i mui 'i he takitaha 'oku qualitative 'a ia 'oku manifinifi ai 'a e fakamatala 'o e maketi ..

Tu'unga

Ko e me‘a ‘oku sivi‘i ‘e he tokotaha fakataú .

Ngaahi Peptiiti Kelaiti Tali vaivai .

Tali malohi .

Tali

Method transfer and pilot-batch scheduling

Peptides angamaheni Multi-month slot queues, high MOQs

Named transfer window, Lomiʻi ʻi he Kemisi Peptides . pilot-to-kilogram path

Specialized modifications

Modification portfolio and sequence complexity handled

Catalog-only list

Specific modification types with precedent

Ko e mahinongofua faka'analaiso

CoA fields and method documentation

Purity percentage alone

Founga, kolomu, and lot-to-lot comparability data

Technical collaboration

Scale-up handoff and transfer support

Handoff at purchase order

Documented transfer plan across mg to kg

Tu'unga 1 mo e 2: Tali mo e ngaahi liliu makehe .

These two criteria are measured in elapsed time and chemistry classes, not in tonnes. Responsiveness means method-transfer and pilot-batch lead time; specialized modifications means whether a supplier can hold a non-standard chemistry through scale-up.

On responsiveness, the structural contrast is utilization. Bachem’s H1 2025 results describe growth as coming from utilization of existing facilities rather than new capacity, which is the pattern buyers meet as slot scheduling and high MOQs on early-stage pilot batches. GenScript’s FY2025 results disclose no turnaround benchmark on the pages reviewed, so published lead times remain a qualitative range: roughly two to three weeks for standard sequences and three to six weeks for complex ones, figures that appear mainly in commercially motivated sources and should be treated as a range, not a market statistic.

Maʻa e custom peptide synthesis capabilities, evaluate by chemistry class rather than service bullets. PEGilaisi, fakasaikale, glycopeptides and isotope labeling each carry different failure modes, and the question is whether the supplier holds the modification through scale-up. Four sequence properties predict difficulty: hydrophobicity and aggregation tendency, loloa 'o e seini, fakalelei'i 'o e ngaahi saiti lahi, and disulfide topology. Each maps to a capability, not a catalog entry.

Mo e Tip .: Run the buyer-side evaluation sequence in order: difficult-sequence feasibility check, pea specialized peptide modifications capability check, then analytical package review, then the scale-up and tech-transfer conversation.

Tu'unga 3: Ko e Mahino Faka'analaiso Ko e Claim Faingata'a Taha ia ke Loi .

a representative batch CoA layout with the HPLC chromatogram, MS 'o e 'ata, purity figure and method fields called out and labelled

Analytical transparency is the one criterion a buyer can verify before committing, which makes it the highest-signal screen in the framework. A batch certificate of analysis is not proof on its own. What matters is whether it carries the fields a filing needs: an HPLC chromatogram with the method and column conditions, an MS spectrum confirming the expected mass, a purity figure tied to a defined method, and a stated endotoxin result.

Endotoxin thresholds tighten with the assay, and the default specification rarely matches the application. One testing-vendor resource reports that levels below 1.0 EU/mg are generally acceptable for immortalized cell lines, ʻi lalo 0.05 EU/mg for primary immune cells, mo e 0.1 ki 0.5 EU/mg for in vivo rodent studies, with USP 〈85〉 injectable limits set at 5 EU/kg/hr on a different unit basis (Creative Proteomics endotoxin and sterility testing resource, ta'e'aho). That is a single vendor source, and the USP 〈85〉 figure should be re-verified against the chapter itself before it anchors a specification.

The honest limitation: USP’s 〈1503〉 vahe ki he ngaahi 'ulungaanga 'o e tu'unga lelei 'o e synthetic peptide mo e ICH Q6B 'a e fa'unga ki he ngaahi fakaikiiki 'oku fakatonuhia'i na'e 'ikai lava ke lau 'i he tohi kakato 'i he paasi ko 'eni ., ko ia 'oku malolo 'a e fakakikihi 'o e ngaahi tohi heni 'i he tafa'aki 'o e supplier mo e naunau hono ua kae 'ikai ko e ngaahi tu'unga mo'ui 'iate kinautolu pe ..

Tu'unga 4: Ko e Fengaue'aki Fakatekinikale mo e Tu'uaki 'o e Scale-Up

Ko e fengaue'aki fakatekinikale ko e me'a ia 'oku ne fakapapau'i pe 'oku tali ., ngaahi fakalelei'i mo e 'analaiso 'o e mahino 'oku mo'ui 'a e puna mei he pailate ki he kulupu fakakomesiale .. 'E lava ke sio malohi ha tokotaha fakatau 'i he me'afua milikalami pea kei ta'elavame'a 'a e handoff .: 'oku tafe 'a e ma'a, 'oku vaivai 'a e fakafehoanaki 'o e kulupu ki he kulupu, pea ʻoku maʻu tofiʻa ʻe he timi talitalí ha founga ʻoku ʻikai ke ne lava ʻo toe fakatupu .. Ko ia ai, ko e fengaue'aki fakatekinikale 'a e Peptide CDMO ko ha tu'unga fili ., 'ikai ko ha anga faka'apa'apa.

MOL Changes, ko e fakatātā ʻe taha ʻi loto ʻi he faʻunga ko ʻení ., 'oku ne fakamatala'i 'a e ongo sourcing extremes 'oku ne tu'u 'o fakafepaki'i .: “fili pe ko ha kautaha fakalakalaka mo e ngaohi'anga koloa 'o e aleapau tier-1 'e taha . (CDMO) pe falala pē ki ha totongi ma‘ama‘a ., tokotaha tu'uaki kataloko ta'efakamo'oni'i. Ko e ongo me‘a fakatu‘utāmakí fakatou‘osi ‘okú na fakahū mai ‘a e fakatu‘utāmaki fakasistema.” ‘Oku pehē ‘e he peesi tatau . Kemisi 'o e Peptide ko ha maʻuʻanga tokoni hono ua māfana ., tauhi ke mo'ui 'o fakafou 'i he fanga ki'i vahenga 'ota fakata'u ., motuhi 'a e ngaahi taimi liliu 'o e kau tu'uaki fakavavevave mei he 12 māhina ki lalo ʻi he 3 uike 2. Tokanga’i ‘a e me’a ko ia ko e sipinga ‘o e sevesi ‘oku fakaha ‘e he brand ., 'ikai ko ha fakafuofua tau'ataina .; ko e keisi fakangaue ki ha ma’u’anga tokoni hono ua mafana ‘oku makatu’unga ia ‘i he palani hokohoko ‘a e tokotaha fakatau ..

Ko e founga kehe ma'ama'a 'oku 'ikai lava 'i ha feitu'u 'oku lava ke tomu'a tala .. Ko e kau tu'uaki 'oku nau tala'ofa 'a e liliu vave 'oku fa'a 'ikai ha ngaahi pule'i 'o e sterility 'o e loki ma'a ., me'angaue 'analaiso fefeka, pe fakafehoanaki 'o e kulupu 'o e lot-ki-lot ., 'a ia ko e ngaahi tohi tonu ia 'oku fie ma'u 'e ha batch fakakomesiale .. Ngaahi Kautaha Fakatahataha'i 'o e Peptide

Founga ke Ngāue‘aki ‘a e Fa‘unga .

ko e hokohoko 'o e sivi'i 'o e ngaahi tu'unga 'e fa ko ha tafe mei he to'ohema ki he to'omata'u ., mo e meʻa fakaʻofoʻofa ʻoku siviʻi ʻi he sitepu takitaha ʻoku fakahaaʻi ʻi lalo aí .

Kamata 'aki hono 'ave ha tokotaha fakatau 'a e hokohoko 'oku ne 'oatu mo'oni 'a e faingata'a kiate koe ., 'ikai ko ha peptide kataloko .. Ko ha synthesis 'ahi'ahi 'i ho'o hokohoko faingata'a mo'oni ko e founga vave taha ia ke vakai pe 'oku ma'u 'e he tali 'a e kole ., pea 'oku 'aho lahi kae 'ikai ko ha siakale sivi'i kakato .. Peptides kuo faka'ilonga'i 'aki 'a e Isotope

  1. Fekau'i atu 'a e hokohoko faingata'a ki ha synthesis 'ahi'ahi .. Ngaahi 'aho. Ko e filter vave taha eni 'oku ke ma'u ..

  2. Kole 'a e lisi 'o e ngaahi fakalelei'i mo e ngaahi kemikale kuo fakahingoa .. Fehu'i pe ko hai 'iate kinautolu 'oku hao mei he scale-up ., ‘ikai ko e ngaahi me‘a pē ‘oku hā ‘i ha polosiua .. Ikuna vave.

  3. Kole ha CoA batch mo'oni pea lau 'a e ngaahi mala'e 'o e founga ., 'ikai ko e fika ma'a pe .. Ikuna vave.

  4. Fakaava ha talanoa tech-fe'ave'aki 'oku ne 'ufi'ufi 'a e hala mg ki he kg . mo e handoff 'o e ngaahi tohi .. Taimi loloa ange.

  5. Fakafe'unga'i ha ma'u'anga tokoni hono ua mafana mo ha vahenga fakata'u si'isi'i .. Taimi loloa ange, pea ko e sitepu ‘oku fakalaka ai ‘a e tokolahi taha ‘o e kau fakataú kae ‘oua kuo fakamālohi‘i ia ‘e ha fakatu‘utāmaki ..

Pepa sikoa: carry the four criteria (tali tali, ngaahi fakalelei makehe, 'analaiso 'a e mahino, technical collaboration) into the supplier call as a one-page grid, and score each answer against the artifact you were shown.

Measure the framework by method-transfer elapsed time, batch-to-batch comparability, and whether the analytical package clears your filing review without follow-up queries. Those three signals are the operational lever behind Bachem’s H1 2025 ngaahi ola, where utilization, not catalog breadth, moved the margin line. Expect the first three steps to change your shortlist within one evaluation cycle.

Ngaahi Fakatokanga: Ko e Feituʻu ʻoku Kei Maʻu Ai ʻa e Vakai Angamaheni .

For a late-stage commercial program with fixed, multi-year demand, tier-1 scale and a regulatory track record genuinely reduce risk, and the four criteria above do not replace that. Slot scheduling and minimum order quantities bite hardest at development and early-clinical scale, ‘a ia ko e feitu‘u ia ‘oku ngāue‘aki mālohi taha ai ‘a e fa‘unga ko ení ..

Ko e ongo fakangatangata 'oku taau ke fakahingoa .. Ko e tafa'aki GenScript 'o e fakafehoanaki ko 'eni 'oku makatu'unga ia 'i he fakahaa'i fakapule'anga manifinifi ange 'i he tafa'aki Bachem ., ko ia 'e lava ke fakahaa'i 'e he konga 'o e asymmetry 'a e to'onga fakahaa'i kae 'ikai ko e malava .. Pea ko e compression ‘a e tafa’aki ‘o Bachem ‘oku ne fakaha ‘e ia pe ‘oku palani mo fakataimi ., ko ha fakafōtunga totonu ange ʻi he tenge ʻo e tafaʻakí pē; na’e fakahā ‘e he kautaha . 2026 faka'amu 'o e lahi ange 'i he CHF . 1 piliona ʻi he fakataú pea laka hake ʻi he 100.000. 30% EBITDA 'o e tafa'aki, hange ko e H1. 2025 'atā, 'oku 'ikai ko e fakamatala 'o ha tokotaha fakatau 'oku mole 'a e kelekele ..

Ko e claim 'oku 'ikai ko e me'afua 'oku ta'e'aonga .. Ko e me'afua ko ia kuo tuku ke fe'unga 'iate ia pe ..

Ngaahi Fehuʻi ʻOku Faʻa ʻEke

Ka ‘oku ‘ikai ke malu’i kitautolu ‘e ha me’afua tier-1 CDMO kapau ‘e ‘alu hake ‘a e fiema’u .?

‘Oku malu’i ‘e he me’afua ‘a e throughput ‘a e tokotaha fakatau, 'ikai ko ho tu'unga laine. Na’e fakahā ‘e he kautaha . 2026 Ko e faka'amu 'i he ngaahi CDMO lalahi ke fakafonu 'a e malava 'aki 'a e ngaahi polokalama 'oku 'osi ma'u 'a e ngaahi slot kuo ta'ofi ., ko ia ko e spike ko e taimi tonu ia 'oku tatali fuoloa taha ai ha tokotaha fakatau ta'efaka'ehi'ehi .. Ko e malu'i 'oku ke fie ma'u ko ha ma'u'anga tokoni hono ua mafana mo ha slot kuo ta'ofi ., 'ikai ko ha palaimeli lahi ange.

Fefe kapau kuo tau 'osi qualify ha supplier lahi pea 'oku fakamole lahi 'a e liliu .?

'Oku 'ikai fiema'u ke ke liliu .. Fakafe'unga'i ha ma'u'anga tokoni hono ua 'i he tafa'aki 'o e tokotaha 'oku lolotonga 'i he lakanga ., 'a ia ko e me'a ia 'oku fakamatala'i 'e he keisi fakangaue ki ha ma'u'anga tokoni hono ua mafana .: ngaahi vahenga fakata'u iiki 'oku nau tauhi 'a e fetu'utaki mo e ngaahi tohi lolotonga ., ko ia ko ha liliu fakavavevave ko ha telefoni ia kae ʻikai ko ha fakamoʻoni ako foʻou .. Ko e tokotaha 'oku lolotonga 'i he lakanga 'oku ne tauhi 'a e voliume .; ko e ma'u'anga tokoni hono ua 'oku ne tauhi koe ke ke 'ufi'ufi ..

'Oku anga fefe ho'o tali ki he fakakikihi 'oku 'ikai lava 'e he kau fakatau 'o e boutique 'o poupou'i 'a e ngaahi voliume fakakomesiale .?

Ko e fakakikihi ko ia ‘oku ne fakataha’i ‘a e pisinisi kataloko ‘a e boutique mo ‘ene ngaahi malava synthesis peptide angamaheni .. ‘Oku fakahaa’i ‘e he ola ‘o e GenScript’s FY2025 ‘a e founga ‘oku ngaue ai ‘a e tu’unga fakaako tupulaki ‘oku fakalele ‘e he laiseni ‘i he tu’unga ., and the same qualification logic applies downward: what matters is whether the supplier can document method transfer, lot comparability and scale-up continuity, not whether its name is large. Ask for the transfer record, not the headcount.

Isn’t analytical transparency just a matter of asking for the CoA?

ʻIkai. A CoA is a summary; peptide analytical data transparency is whether the underlying method, the lot it was run on and the specification it was judged against travel with the number. Endotoxin thresholds tighten with the assay, so a certificate that reports a value without the method and limit tells you little. Ask which assay, which lot, which specification, and whether peptide CDMO technical collaboration extends to reviewing the data with you.

Aofangatuku: Ko e Meʻa ʻOku Totonu ke Kole ʻe he Kau Fakataú ʻi he 2019. 2026

Scale is now table stakes in peptide supplier selection criteria, and the four criteria that actually separate suppliers are responsiveness, ngaahi fakalelei makehe, analytical transparency and technical collaboration. Bachem’s H1 2026 results make the point: net sales rose 4.3% ki he CHF 326.4 million while the EBITDA margin fell 3.7 percentage points to 25.4% (Bachem’s H1 2026 ngaahi ola, Siulai 2026). Capacity growth no longer guarantees pricing power or service quality.

So ask for artifacts, not assurances. Request a representative CoA with the analytical method behind each specification, a written list of modifications the supplier has actually delivered, and a named technical contact who owns the scale-up handoff. Where suppliers publish nothing comparable, treat the gap as a finding: GenScript’s FY2025 results show how little peptide-specific disclosure reaches buyers who need to compare (Ko e ola ‘o e GenScript ‘i he FY2025). The market improves when the CoA, the modification list and the transfer path become the comparison surface.

If you are evaluating suppliers now, request a representative CoA package and a technical consultation before you commit to a slot.

This article is published by MOL Changes, which offers custom peptide synthesis and analytical documentation services. Consider that interest when weighing the framework above.

Sejun Pengi

Sejun Pengi

'Ofisa Pule Tekinolosia; Mataotao 'i he fakatahataha'i 'o e Peptide Taukei Tefito: Fakatahataha'i 'o e peptide faingata'a, ngaahi fakalelei'i 'o e 'esiti 'amino 'ikai fakanatula, mo e langa 'o e ngaahi peptides 'o e siakale mo e ngaahi peptides 'o e stapled ..

Piokālafi:'Oku lahi 'a e a'usia 'a Zejun Peng 'i he kemikale 'o e 'okani mo e synthesis 'o e peptide .. 'Oku ne taukei 'i he fakataha'i 'o e tohi kole 'o e synthesis peptide fefeka-vahe . (SPSS) mo e synthesis 'o e peptide 'o e vai-vahe . (LPPS), pea tautefito ‘ene taukei ‘i hono ikuna‘i ‘a e “ngaahi hokohoko ‘oku mātu‘aki faingata‘a ke fakatahataha‘í” . (hange ko e peptides ultra-loloa-seini ., ngaahi hokohoko 'o e hydrophobic ma'olunga, mo e ngaahi fehokotaki'anga disulfide lahi 'oku fakafonu .). ‘I he malumalu ‘o ‘ene takí ., kuo lavame'a 'a e timi 'i hono ikuna'i 'o e ngaahi bottlenecks fakatekinikale 'i ha ngaahi fakalelei'i makehe . (hange ko e N-metilasi ., PEGilaisi, mo e faka'ilonga'i 'o e fluorescent .), tauhi ha tu'unga lavame'a 'o e synthesis 'o e 'olunga 'i he 100. 98%.

Sivi'i 'a e Mo'oni & Ngaahi Fakahinohino Faka-ʻEtita
Toe vakaiʻi ʻe he .: Kau Mataotao ʻi he Kaveingá
Vahevahe 'a e fakamatala ko 'eni .
Api Kumi Whatsapp Ngaahi Sevesi Koloa